The Future of Nuclear Medicine as an Independent Specialty

Czernin, Johannes; Sonni, Ida; Razmaria, Aria; Calais, Jérémie

doi:10.2967/jnumed.118.220558

Cited by 47 publications

(34 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with traditional imaging, molecular imaging can qualitatively or quantitatively provide molecular information about diseases before anatomical changes, which not only improves the specificity, sensitivity, and accuracy of diagnosis but also effectively improves the rate of early diagnosis so as to achieve "early detection, early diagnosis, and early treatment." The biomarkers used for molecular imaging include peptides, antibody, and antibody fragments (13), which allow to qualitatively and quantitatively trace biological behaviors. Compared with other imaging methods, nuclear molecular imaging can obtain more sensitive in vivo images using radiolabeled probes, which plays an important role in basic research and clinical diagnosis (14).…”

Section: Introductionmentioning

confidence: 99%

Down-Regulation of Toll-Like Receptor 5 (TLR5) Increased VEGFR Expression in Triple Negative Breast Cancer (TNBC) Based on Radionuclide Imaging

et al. 2021

View full text Add to dashboard Cite

In this study, GFP-tagged TNBC 4T1 cells with down-regulated TLR5 expression (TLR5− 4T1) and normal TLR5 expression (TLR5+ 4T1) were constructed, respectively. RT-PCR and Western blot studies showed that down-regulation of TLR5 obviously increased the expression of VEGFR in 4T1 cells. Highly stable radio-probes 125I-anti-TLR5 mAb/125I-VEGF/125I-IgG were obtained with labeling rates over 85% and radiochemical purities above 90%. Among these three probes, 125I−anti−TLR5 mAb and 125I-VEGF were used for specifically imaging TNBC, while 125I-IgG was used for comparison. Whole-body phosphorus autoradiography showed clear imaging at 48 h after injection of 125I-anti-TLR5 mAb and 125I-VEGF also provided clear imaging at 24 h. Biodistribution study demonstrated a higher tumor uptake of 125I-anti-TLR5 mAb in TLR5+ group compared with that in TLR5− group (P < 0.05), whereas tumor uptake of 125I-VEGF in TLR5+ group was lower than that in the TLR5− group (P < 0.05). Immunohistochemical staining suggested that the expression of TLR5 was lower, whereas the expression of VEGFR, CD31, and MVD (microvessel density) was higher in TLR5− tumor-bearing mice. In summary, the down-regulation of TLR5 in TNBC promoted the VEGFR expression and angiogenesis, resulting in the proliferation of TNBC cells. TLR5/VEGF might be a better indicator for monitoring the development of TNBC.

show abstract

Section: Introductionmentioning

confidence: 99%

Down-Regulation of Toll-Like Receptor 5 (TLR5) Increased VEGFR Expression in Triple Negative Breast Cancer (TNBC) Based on Radionuclide Imaging

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, nuclear medicine needs to strengthen its position as a unique profession in daily, multidisciplinary clinical routine. Therefore, a clear, independent profile emphasizing specific strengths compared with neighboring disciplines (e.g., oncology, radiology, and radiation oncology) needs to be refined by, for example, updated licensing of training programs (12). In addition, nuclear medicine theranostics is currently regarded as an interesting business model by many companies.…”

mentioning

confidence: 99%

Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine

2019

View full text Add to dashboard Cite

Molecular alterations in malignant disease result in the expression or upregulations of various targets that can be used for imaging and treatment with radiopharmaceuticals. This theranostic principle has acquired greater importance in personalized medicine in recent years, particularly in oncology, where advanced tumors can be treated effectively with low side effects. Since the pioneering use of 131 I in differentiated thyroid cancer in the 1940s, remarkable achievements in nuclear medicine endoradiotherapy have been demonstrated, mainly in the treatment of neuroendocrine neoplasms by using 177 Lulabeled somatostatin analogs or in the treatment of advanced prostate cancer using prostate-specific membrane antigen-directed radionuclide therapy. Besides that, this review focuses on promising novel radiopharmaceuticals and describes their preclinical and clinical status. Radiolabeled antibodies, such as 131 I-omburtamab directed against the B7-H3 protein on the surface of neuroblastoma cells; HuMab-5B1, a 89 Zr/ 177 Lu-labeled antibody for the treatment of CA19-9-expressing malignancies; and 177 Lu-lilotomab, a CD37 antibody for the treatment of B-cell lymphomas, are being highlighted. The neurotensin receptor ligand 111 In/ 177 Lu-3B-227 has demonstrated high potential in imaging and therapy for several malignancies (e.g., pancreatic adenocarcinomas). Targeting of the fibroblast activation protein is currently being explored for different tumor entities using PET imaging with the fibroblast activation protein inhibitor (FAPI) 68 Ga-FAPI-04, and the first therapeutic applications of 90 Y-FAPI-04 have been applied. After 2 decades of rapid development in theranostics, a variety of new targets are available for further clinical investigation.

show abstract

“…PET relies on positron-emitting nuclides for imaging, mainly including 18 F, 68 Ga, etc., while SPECT relies on single-photon-emitting nuclides and 99m Tc is mainly used in clinical applications. Since PET and SPECT are important functional imaging methods with high sensitivity and specificity, they have been applied to tumors, central nervous system (CNS) and cardiovascular system (20)(21)(22)(23)(24)(25). With the continuous development and progress of MI, PET and SPECT as important parts of MI have also made considerable progress in recent years.…”

mentioning

confidence: 99%

A review of the application of machine learning in molecular imaging

Yin¹,

Cao²,

Wang³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Molecular imaging (MI) is a science that uses imaging methods to reflect the changes of molecular level in living state and conduct qualitative and quantitative studies on its biological behaviors in imaging. Optical molecular imaging (OMI) and nuclear medical imaging are two key research fields of MI.OMI technology refers to the optical information generated by the imaging target (such as tumors) due to drug intervention and other reasons. By collecting the optical information, researchers can track the motion trajectory of the imaging target at the molecular level. Owing to its high specificity and sensitivity, OMI has been widely used in preclinical research and clinical surgery. Nuclear medical imaging mainly detects ionizing radiation emitted by radioactive substances. It can provide molecular information for early diagnosis, effective treatment and basic research of diseases, which has become one of the frontiers and hot topics in the field of medicine in the world today. Both OMI and nuclear medical imaging technology require a lot of data processing and analysis. In recent years, artificial intelligence technology, especially neural networkbased machine learning (ML) technology, has been widely used in MI because of its powerful data processing capability. It provides a feasible strategy to deal with large and complex data for the requirement of MI. In this review, we will focus on the applications of ML methods in OMI and nuclear medical imaging.

show abstract

The Future of Nuclear Medicine as an Independent Specialty

Cited by 47 publications

References 80 publications

Down-Regulation of Toll-Like Receptor 5 (TLR5) Increased VEGFR Expression in Triple Negative Breast Cancer (TNBC) Based on Radionuclide Imaging

Down-Regulation of Toll-Like Receptor 5 (TLR5) Increased VEGFR Expression in Triple Negative Breast Cancer (TNBC) Based on Radionuclide Imaging

Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine

A review of the application of machine learning in molecular imaging

Contact Info

Product

Resources

About